The next frontier in medicine: drugs designed by artificial intelligence

Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.

Solution News Source

The next frontier in medicine: drugs designed by artificial intelligence

Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.

Solution News Source

SIGN UP

TO GET A Free DAILY DOSE OF OPTIMISM


We respect your privacy and take protecting it seriously. Privacy Policy